Skindex-Mini Among Patients With Melanoma Who Have Cutaneous Immunotherapy-Related Adverse Effects

• Type of Material: Article
• Authors: Howa Yeung, Emory University; Krittin J Supapannachart, Emory University; Emily Cole, Emory University; Suephy Chen, Emory University
• Language: English
• Date: 2021-10-22
• Publisher: SAGE PUBLICATIONS INC
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © The Author(s) 2021.
• Final Published Version (URL): http://dx.doi.org/10.1177/12034754211051239
• Title of Journal or Parent Work: JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
• Volume: 26
• Issue: 2
• Start Page: 212
• End Page: 213
• Grant/Funding Information: This present study was supported in part by the American Skin Association (HY), the American Cancer Society and Melanoma Research Alliance Pilot Award (SC, HY), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases under award numbers L30AR076081 and K23AR075888. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.
• Keywords: Life Sciences & Biomedicine; quality of life; melanoma; Skindex-mini; Science & Technology; Dermatology; immunotherapy; itch

Abstract

Immune checkpoint inhibitors have improved survival among patients with advanced melanoma but commonly cause cutaneous immunotherapy-related adverse effects.1 Health-related quality of life impacts (HRQOL) of common cutaneous immunotherapy-related adverse effects are not well studied because validated tools can be challenging to incorporate into clinical visits.2,3 This study aimed to determine whether Skindex-mini, a short 3-item questionnaire, correlated with Skindex-16, in assessing skin-specific symptoms, emotional, and functional impact on HRQOL, in patients with advanced melanoma who developed immunotherapy-related cutaneous adverse effects.